MO HB1020

Oncologists and health care providers may voluntarily notify the Missouri Department of Health and Senior Services if they use off-label drugs to treat cancer or terminally ill patients, including which drugs and for what purposes

The department must maintain a database of providers engaged in off-label drug usage as part of the cancer information reporting system, including names, addresses, and specific treatments

Sponsors or investigators of placebo-controlled clinical drug trials must notify the department of their intent to conduct trials in Missouri, and the department must then notify all licensed oncologists and cancer research institutions

Clinical trial sponsors must provide prospective participants with a list of providers offering off-label treatments for similar conditions as part of the informed consent process under 21 CFR 50.25

Sponsors who willfully fail to obtain proper informed consent face a fine of $50,000